Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Female or male aged ≥40 years~* Diagnosed with Type 2 Diabetes~* High Risk for Cardiovascular events~Exclusion Criteria:~* Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time~* Chronic cystitis and/or recurrent urinary tract infections~* Pregnant or breast-feeding patients

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
- Placebo (Type: PLACEBO_COMPARATOR): Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors

Based on this trial design, predict the completion outcome and termination type (if applicable).